anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Genetically predisposed breast cancer (BC) patients represent a minor but clinically meaningful subgroup of the disease, with 25% of all cases associated with actionable variants in BRCA1/2. Diagnostic implementation of next-generation sequencing (NGS) resulted in the rare identification of BC patients with double heterozygosity for deleterious variants in genes partaking in homologous recombination repair of DNA. As clinical heterogeneity poses challenges for genetic counseling, this study focused on the occurrence and clinical relevance of double heterozygous BC in South Africa.
METHODS: DNA samples were diagnostically screened using the NGS-based Oncomine™ BRCA Expanded Research Assay. Data was generated on the Ion GeneStudio S5 system and analyzed using the Torrent Suite™ and reporter software. The clinical significance of the variants detected was determined using international variant classification guidelines and treatment implications.
RESULTS: Six of 1600 BC patients (0.375%) tested were identified as being bi-allelic for two germline likely pathogenic or pathogenic variants. Most of the variants were present in BRCA1/2, including two founder-related small deletions in three cases, with family-specific variants detected in ATM, BARD1, FANCD2, NBN, and TP53. The scientific interpretation and clinical relevance were based on the clinical and tumor characteristics of each case.
CONCLUSION: This study increased current knowledge of the risk implications associated with the co-occurrence of more than one pathogenic variant in the BC susceptibility genes, confirmed to be a rare condition in South Africa. Further molecular pathology-based studies are warranted to determine whether clinical decision-making is affected by the detection of a second pathogenic variant in BRCA1/2 and TP53 carriers.
Electronic phenotyping is a fundamental task that identifies the special group of patients, which plays an important role in precision medicine in the era of digital health. Phenotyping provides real-world evidence for other related biomedical research and clinical tasks, e.g., disease diagnosis, drug development, and clinical trials, etc. With the development of electronic health records, the performance of electronic phenotyping has been significantly boosted by advanced machine learning techniques. In the healthcare domain, precision and fairness are both essential aspects that should be taken into consideration. However, most related efforts are put into designing phenotyping models with higher accuracy. Few attention is put on the fairness perspective of phenotyping. The neglection of bias in phenotyping leads to subgroups of patients being underrepresented which will further affect the following healthcare activities such as patient recruitment in clinical trials. In this work, we are motivated to bridge this gap through a comprehensive experimental study to identify the bias existing in electronic phenotyping models and evaluate the widely-used debiasing methods' performance on these models. We choose pneumonia and sepsis as our phenotyping target diseases. We benchmark 9 kinds of electronic phenotyping methods spanning from rule-based to data-driven methods. Meanwhile, we evaluate the performance of the 5 bias mitigation strategies covering pre-processing, in-processing, and post-processing. Through the extensive experiments, we summarize several insightful findings from the bias identified in the phenotyping and key points of the bias mitigation strategies in phenotyping.
The present invention discloses a ribozyme gene hTERT-5' RZ cDNA for inhibiting telomerase activity, a recombinant carrier containing the gene and ribozyme hTERT-5' RZ for transcribing the recombinant carrier. The ribozyme gene is composed of two 40 nt complementary strands which are annealed to form the ribozyme gene; the nucleotide sequence of the gene is disclosed in the figure 1. The ribozyme gene hTERT-5' RZ cDNA is inserted into the EcoRI-XhoI site of the carries pcDNA3.1(+), and then, the recombinant plasmid pcDNA3.1hTERT-5' RZ is obtained. The recombinant plasmid pcDNA3.1hTERT-5' RZ is cut by XhoI and EcoRI enzymes to be linearized. The ribozyme hTERT-5' RZ can be transcribed via T7RNA pclymerase catalysis by a T7/SP6 in-vitro transcription reagent kit; the secondary structure of the ribozyme is disclosed in the figure 3. The ribozyme hTERT-5' RZ and the ribozyme teloRZ can also form into a dicaryon enzyme. Detection results indicate that the ribozyme hTERT-5' RZ and the dicaryon enzyme can both effectively inhibit tumor growth.
BACKGROUND: Forehead aesthetic injections are a well-known source of discomfort, and many analgesic non-invasive techniques have been proposed to ameliorate pain. However, no study has compared all these techniques for aesthetic purposes. Therefore, this study aimed to compare the effectiveness of topical cream anesthesia, vibratory stimulus, cryotherapy, pressure, and even no intervention, on pain during and immediately after injection, when considering aesthetic injections in the forehead.
METHODS: Seventy patients were selected and had their foreheads divided into 5 parts, which received four different analgesic techniques, and one control zone was added. A numeric rating scale was used to assess pain, two direct questions were asked to evaluate patients' preference and discomfort with the techniques, and the adverse events were quantified. The injections were performed in the same sequence, with three minutes of rest between them and in a single session. Comparisons among analgesic methods for pain relief were performed by the one-way analysis of variance (ANOVA), considering a significance level of 5%.
RESULTS: No significant differences were found among the analgesic methods, and between the methods and the control zone, both during and immediately after the injections (p > 0.05). The preferred method for pain relief was the use of topical anesthetic cream (47%), while the most uncomfortable technique was manual distraction (pressure) (36%). Only one patient reported an adverse event.
CONCLUSIONS: No analgesic method to diminish pain was superior to the others or was better than no method. Nevertheless, the topical anesthetic cream was the preferred technique, causing less discomfort.
LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Empagliflozin 10 mg daily will be administered for 1 year. The patient and the PI will be blinded (unaware) of the group they are assigned to.
Ventricular arrhythmia (VT) is a well-established consequence in patients with non-ischemic cardiomyopathy (NICM). NICM is a broad category that includes a wide spectrum of causes, which may include: bacterial, viral toxin mediated and immune mediated and "unexplained" when coronary disease has been excluded. The pathophysiology of NICM is not well understood but inflammatory responses with macrophage recruitment during remodeling have been described. On the other hand, an infectious trigger i.e. myocarditis may be the inciting event for the development of cardiomyopathy. A previous study by Tung et al showed that nearly 50% of patients with unexplained cardiomyopathy and ventricular arrhythmias presented ongoing focal myocardial inflammation on PET. To date, targeting inflammation as a substrate in order to reduce burden of ventricular tachycardia has not been investigated in randomized prospective fashion.

The TIMIC trial was one of the few randomized studies to examine long-term benefit of immunosuppressive therapies in patients with virus-negative NICM. A moderate improvement in Left Ventricular Ejection Fraction (LVEF) over 6 months after initiation of immunosuppressive therapy was demonstrated in this study but current guidelines do not routinely recommend anti-inflammatory therapies for NICM. While considered to be gold standard, endomyocardial biopsy can often times be incorrect due to sampling error and typically is not performed multiple times in patient with chronic non-ischemic cardiomyopathy. Fasting Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is an emerging imaging modality to identify and monitor abnormal metabolic patterns of the myocardium. By exploiting the metabolic demand of inflammatory tissue with macrophage recruitment, PET imaging is emerging as the preferred modality to diagnose and measure response to therapy for patients with myocarditis and sarcoidosis. A recent study by Kandolin et al in Finland showed that the incidence of cardiac sarcoidosis has increased by 20-fold over the past two decades.

FDG-PET may reveal inflammation as a central pathophysiologic mechanism in a significant proportion of patients with unexplained cardiomyopathy and VT. Potential innovative insights from the trial will be to identify the underlying pathogenesis of idiopathic cardiomyopathy and assess whether immunosuppression changes the clinical course of patients with identified arrhythmogenic cardiomyopathy. Aside from guideline-direct medical therapy (GDMT), antiarrhythmic agents, and catheter ablation, there are no disease-specific therapies for patients with VT and NICM. Prospective studies that evaluate the incidence of occult inflammation and clinical response to anti-inflammatory and immunosuppressive therapy have not been performed to date and are warranted for the emerging NICM population referred for advanced heart failure and arrhythmia management.
PURPOSE:To obtain the brain derived alkali phosphatase (ALP)I specific antibody from the antiserum obtd. by immunizing the brain derived ALPI type isozyme having specific physicochemical properties to an animal. CONSTITUTION:The brain derived ALPI type isozyme which has about 15,000 mol.wt. heat resistance (56 deg.C, 5 minutes), about 60% residual activity, does not hinder phenyl alanine, and has the physicochemical properties, such as immobility in migratability in Triton X treatment and immobility in migratability in neuraminidase treatment is dosed to the animal to immunize. The antibodies which react with the isozymes of the non-brain derived ALPI type, II type and III type in addition to the anti-brain derived ALPI specific antibody reacting specifically with the brain derived ALPI type isozyme are included in the resulted antiserum. The antibodies reacting with the non-brain derived I type, II type and III type isozymes are removed and the anti-brain derived ALPI specific antibody is obtd. if this antiserum is absorbed by using the non-brain derived ALPII type and III type isozymes.
The invention discloses a Chinese traditional medicine ointment for curing skin diseases and corresponding preparing and testing method. The ointment is formed by preparing main raw medical materials and assistant raw medical materials. For every 1000g ointment, the main raw medical materials comprise fresh aloe leaf, rose, radix sophorae flavescentis, smartweed, borneol and pennyroyal; and the assistant raw medical materials comprise stearic acid, stearyl alcohol, glycerin, monoglycerides and polysorbate-80. The preparing method of the Chinese traditional medicine ointment comprises pressing fresh aloe juice, picking up rose aroma water and making radix sophorae flavescentis and smartweed cream to be mixed, then the assistant medical materials are added to make the Chinese traditional medicine ointment. The testing method is the discrimination to the aloe composition, which comprises: (1) making trial product solution, (2) making reference substance solution, (3) discrimination. The Chinese traditional medicine ointment is mainly used for treating acne, skin itch, eczema and solarization sore and has remarkable effect for acne, skin itch universally among the old, bite by midge, hypersusceptibility and eczema, with safety and reliability. Itch can be killed only minutes after applying. Simultaneously, the invention can moisturize and protect skin, have remarkable effect for light hurt of skin and is a preparatory medicine for household.
The invention relates to a specific PPMP-type antigen of Clonorchis sinensis. The nucleotide sequences of the antigen gene are shown in SEQIDNO: 3. The invention also provides an antibody specifically bound to the specific antigen of Clonorchis sinensis, an isolated specific PPMP-type antigen protein of Clonorchis sinensis encoded by the nucleotide sequences of the specific antigen genes of Clonorchis sinensis, a vector containing the specific antigen genes of Clonorchis sinensis and a kit. The invention also provides an application of the specific antigen protein of Clonorchis sinensis, the antibody, vectors and the kit in the preparation of a medicament for the treatment, diagnosis or prevention of clonorchiasis. The specific PPMP-type antigen of Clonorchis sinensis, which is disclosed by the invention, has a higher immunogenicity, and easily used for preparing the multi/monoclonal antibody and can be applied to antigen detection and other aspects. Experimental results show that the experimental animals (mice) have a stronger immune response to the antigen.
OBJECTIVE: Progesterone administration has been associated with improved neurological outcomes following traumatic brain injury in adults. However, studies examining the effect of progesterone on the risk of neonatal intraventricular hemorrhage (IVH) are inconsistent. We sought to determine if maternal administration of intramuscular 17-α-hydroxyprogesterone caproate (17-OHPC) is associated with decreased rates of IVH in infants born before 32-weeks gestation.
STUDY DESIGN: This is a retrospective study of liveborn singleton deliveries between 20- and 32-weeks gestation at two large academic medical centers from January 1, 2012 to August 30, 2020. Data were extracted from hospital electronic medical record data warehouses using standardized definitions and billing and diagnosis codes. We evaluated receipt of 17-OHPC in the antepartum period and diagnosis of IVH (grade I-IV, per Volpe classification) during the neonatal delivery hospitalization encounter. Bivariate and multivariate analyses were performed to examine the association between 17-OHPC and neonatal IVH adjusting for potential confounders. Odds ratio (ORs) and 95% confidence intervals (CIs) were presented.
RESULTS: Among 749 neonates born between 20- and 32-week gestation, 140 (18.7%) of their mothers had received antenatal 17-OHPC and 148 (19.8%) were diagnosed with IVH after birth. No significant association was observed between maternal 17-OHPC and neonatal IVH in unadjusted (OR 1.14, 95% CI 0.72-1.78) or adjusted analyses (adjusted odds ratio 1.14, 95% CI 0.71-1.84). Independent of exposure to 17-OHPC, as expected, infants born <28-weeks gestation or those with very low birthweight (<1,500 g) were at an increased risk of IVH (OR 2.32, 95% CI 1.55-3.48 and OR 2.19, 95% CI 1.09-4.38, respectively).
CONCLUSION: Antenatal maternal 17-OHPC administration was not associated with the risk of neonatal IVH. Further research may be warranted to determine whether timing, route of delivery, and duration of progesterone therapy impact rates of neonatal IVH.
KEY POINTS: · This study aimed to compare the frequency of intraventricular hemorrhage in preterm neonates exposed to antenatal 17-α-hydroxyprogesterone caproate to those not exposed.. · In neonates born at <32-weeks gestation, maternal use of progesterone is not associated with the risk of intraventricular hemorrhage.. · In contrast to preclinical and adult data, this study suggests that progesterone exposure is not associated with the prevention of neonatal brain injury..
China is a country with a high incidence of liver cancer. The latest forecast data of the International Agency for Research on Cancer (IARC) shows that the number of newly diagnosed liver cancer in China in 2020 is close to half of the total in the world. Hepatocellular carcinoma (HCC) is the main type of liver cancer, accounting for more than 85%-90%. About 60% of HCC patients are of advanced stage when first visit, and lose the opportunity to receive radical treatment. Currently, targeted drugs are recommended by the guidelines for first-line treatment of advanced HCC. Several studies have shown that the use of immune checkpoint inhibitors (mainly PD-(L)1 inhibitors) combined with targeted drugs can increase the survival benefits of patients with advanced HCC. However, the overall ORR of first-line treatment is less than 50%, and some patients have experienced high-grade adverse events.

Huaier granules is an extract from a medicinal fungus. Previous studies have shown that Huaier granules can inhibit the proliferation, angiogenesis, metastasis and invasion of cancer cells, and can reverse the resistance of targeted drugs. Huaier granules is one of the most commonly used Chinese patent medicines in the treatment of HCC, and is recommended by CSCO guidelines（liver cancer）. Several previous studies have shown that Huaier granules can improve the efficacy and reduce the incidence of adverse events in all stages of HCC treatment.

In this study, about 10 research centers will participate. The study will enroll 600 participants. The experimental group will enroll 200 participants who will be treated with Huaier granules combined with targeted drug and anti- PD-(L)1 antibody, the three specific treatment regimens were Huaier granules combined with Atezolizumab and Bevacizumab, Huaier granules combined with Camrelizumab and Apatinib, Huaier granules combined with Sintilimab and Bevacizumab. The control group will enroll 400 participants who will be treated with targeted drug combined with anti-PD-(L)1 antibody, the three specific treatment regimens were Atezolizumab combined with Bevacizumab, Camrelizumab combined with Apatinib, Sintilimab combined with Bevacizumab. In this study, participants will be followed up for 12 months.
BACKGROUND: Benign uretero-ileal anastomotic stricture (UIAS) is a potentially serious complication that can arise after radical cystectomy (RC) and subsequent urinary diversion. To preserve residual renal function and improve prognosis, it is crucial to derive insights from experience and tailor individualized treatment strategies for different patients.
PATIENTS AND METHODS: From October 2014 to June 2021, a total of 47 patients with benign UIAS underwent endoscopic management (n = 19) or reimplantation surgery (n = 28). The basic data, perioperative conditions, and postoperative outcomes of the two groups were compared and analyzed to evaluate efficacy.
RESULTS: Comparing preoperative and postoperative clinical efficacy within the same group, the endoscopic group showed no significant differences in creatinine and blood urea nitrogen (BUN) levels before surgery or after extubation (p > 0.05). However, significant differences were observed in glomerular filtration rate (GFR) levels on the affected side before surgery and after extubation (p < 0.05). In contrast, the laparoscopic reimplantation group did not exhibit significant differences in creatinine, BUN, or GFR levels of affected side before surgery and after extubation (p > 0.05). Postoperative clinical efficacy showed no significant difference in creatinine and BUN levels between the two groups (p > 0.05). However, GFR values of affected side in the endoscopic treatment group decreased more than those in the laparoscopic reimplantation group (p < 0.05). Additionally, the laparoscopic reimplantation group was able to remove the single-J tube earlier than the endoscopic treatment group (p < 0.05), had a lower recurrence rate of hydronephrosis after extubation (p < 0.05), and experienced a later onset of hydronephrosis compared to the endoscopic treatment group (p < 0.05).
CONCLUSIONS: Based on our experience in treating UIAS following RC combined with urinary diversion, laparoscopic reimplantation effectively addresses the issue of UIAS, allowing for the removal of the ureteral stent relatively soon after surgery. This approach maintains long-term ureteral patency, preserves residual renal function, reduces the risk of ureteral restenosis and hydronephrosis, and has demonstrated superior therapeutic outcomes in this study.
This is a Phase II, open-label, multi-centre study to determine safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) monotherapy in participants with unresectable Stage III NSCLC who have not progressed following definitive, platinum-based sCRT. Approximately, 150 participants will be treated with the study drug in Europe and North America. Participants will be in complete response (CR), partial response (PR), or have stable disease (SD) following definitive, platinum-based sCRT, as assessed by the Investigator and further supported by the screening imaging radiological assessment. Participants must not have progressed following definitive, platinum-based sCRT; radiation therapy must be completed within 42 days prior to first Investigational product (IP) dose administration. Participants must have histologically- or cytologically-documented NSCLC and locally-advanced, unresectable Stage III disease. Participants will be treated with the study drug in 2 cohorts: approximately 100-120 participants in the World Health Organization/Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) 0 to 1 Cohort and up to 30 participants in the WHO/ECOG PS 2 Cohort.
Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
Antibody reactivities are traditionally studied by their individual reactivities to one or only a few antigens, whereas only a small number of studies have focused on the repertoires of antibodies to large numbers of defined antigens. Only recently, a new technology for system level analysis, the immune microarrays (or antigen chips) was introduced \[Quintana 2004, Quintana and Cohen 2004, Robinson 2006\]. This technology is capable of detecting patterns of antibodies binding to many hundreds of antigens, foreign or self and thus allowing a systems biology view of immune system. To create the antigen chips, a robotic apparatus is used to spot the antigen molecules of choice - proteins, peptides, sugars, lipids, nucleic acids - to a coated glass slide. These antigens are covalently linked to the surface of the slide and a drop of blood serum or any other body fluid can be tested for antibodies binding to hundreds of these antigen spots. The subject's bound antibodies are detected using fluorescence-labeled second antibodies and the reactions are monitored by laser activation.